In studies of the fertility of migrants in which the data are confined to the migrants only, estimation bias will normally appear in comparisons of childbearing before and after migration. The same issue arises in studies of union formation before and after first birth, marriage formation before and after home purchase, and in any other comparison of behaviour before and after an index event if one confines the study only to those who have experienced the index event. It is normally better to avoid analysis of behaviour before the index event because such analysis actually conditions on the later arrival of the index event. In this paper, we provide graphical and mathematical representations of this problem and show how one can get a meaningful (unconditional) comparison of behaviour before and after the index event provided the data contain enough information for both sub-periods. Otherwise, the analyst should refrain from making a comparison of this nature.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00324728.2013.843019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Remote Ischemic Conditioning Attenuates Transneuronal Degeneration and Promotes Stroke Recovery via CD36-Mediated Efferocytosis.
Circ Res
January 2025
Burke Neurological Institute, White Plains, NY (H.J., I.P., K.W.P., J.M., A.M., S.C.).
Background: Remote ischemic conditioning (RIC) has been implicated in cross-organ protection in cerebrovascular disease, including stroke. However, the lack of a consensus protocol and controversy over the clinical therapeutic outcomes of RIC suggest an inadequate mechanistic understanding of RIC. The current study identifies RIC-induced molecular and cellular events in the blood, which enhance long-term functional recovery in experimental cerebral ischemia.
View Article and Find Full Text PDFManagement and Outcomes of Type I and Type II Myocardial Infarction in Cardiogenic Shock.
CJC Open
February 2024
CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Background: Type I myocardial infarction (T1MI) or type II myocardial infarction (T2MI) have different underlying mechanisms; however, in the setting of cardiogenic shock (CS), it is not understood if patients experience resultantly different outcomes. The objective of this study was to determine clinical features, biomarker patterns, and outcomes in these subgroups.
Methods: Patients from the CAPITAL-DOREMI trial presenting with acute myocardial infarction-associated CS (n = 103) were classified as T1MI (n = 61) or T2MI (n = 42).
Objective: Our objective of this study was to analyse all oncological clinical trials using regorafenib to create a complete risk/benefit profile for the drug.
Background: Creating a novel chemotherapy is costly both in time and capital spent for drug manufacturers. To regenerate what they've spent, drug manufacturers may attempt to repurpose their medications for new indications via clinical trials.
Cancer incidence and competing mortality risk following 15 presenting symptoms in primary care: a population-based cohort study using electronic healthcare records.
BMJ Oncol
November 2024
Department of Behavioural Science and Health, Institute of Epidemiology and Healthcare, University College London, London, UK.
Objectives: Assessment of age, sex and smoking-specific risk of cancer diagnosis and non-cancer mortality following primary care consultation for 15 new-onset symptoms.
Methods And Analysis: Data on patients aged 30-99 in 2007-2017 were extracted from a UK primary care database (CPRD Gold), comprising a randomly selected reference group and a symptomatic cohort of patients presenting with one of 15 new onset symptoms (abdominal pain, abdominal bloating, rectal bleed, change in bowel habit, dyspepsia, dysphagia, dyspnoea, haemoptysis, haematuria, fatigue, night sweats, weight loss, jaundice, breast lump and post-menopausal bleed).Time-to-event models were used to estimate outcome-specific hazards for site-specific cancer diagnosis and non-cancer mortality and to estimate cumulative incidence up to 12 months following index consultation.
A bibliometric study on the impact of gut microbiota on the efficacy of immune checkpoint inhibitors in cancer patients: analysis of the top 100 cited articles.
Front Immunol
January 2025
School of Basic Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Background: Immune checkpoint inhibitors (ICIs) have transformed oncological treatment by modulating immune responses against tumors. However, their efficacy is subject to inter-patient variability and is associated with immune-related adverse events (irAEs). The human gut microbiota, a complex microbial ecosystem, is increasingly implicated in modulating responses to ICIs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!